This finding aligns with a recent meta-analysis involving 29,156 individuals from 30 studies, which demonstrated that serum FGF21 concentrations were significantly higher in patients with CVD (p < 0.001), particularly in those with CAD and hypertension (p < 0.001). This evidence concerns the gene FGF21 and hypertensive disorder.